pharmaphorum

JULY 19, 2021

A new report published by Medicines Discovery Catapult and CPI details the huge medical and market potential for complex medicines in the UK. The market value for complex medicines is set to reach hundreds of billions of pounds, and you can see why with the potential benefits for patients.”. Click here to read the full report.

Life Science 52

Life Science Medicine RNA Vaccination 52

XTalks

DECEMBER 10, 2021

Zavegepant is an antibody drug that prevents binding of the calcitonin gene-related peptide (CGRP) to the CGRP receptor. CGRP receptor antagonists are a new class of antibody drugs used for migraine treatment. The pain relief effects were sustained for up to 48 hours.

FDA Approval 98

FDA Approval Trials Drugs Sales 98

XTalks

FEBRUARY 29, 2024

In a statement , the company said it will discontinue Aduhelm to focus efforts on its other amyloid beta-directed antibody Leqembi (lecanemab) for Alzheimer’s and focus on developing other new treatments. After its accelerated approval in January 2023, Leqembi received full US Food and Drug Administration (FDA) approval in July 2023.

Drugs 59

Drugs FDA Approval Antibody Life Science 59

Drug Discovery World

JULY 2, 2024

DDW’s Diana Spencer takes a closer look into why Switzerland is such a life sciences powerhouse and how Swiss researchers are advancing new technology and tackling modern health challenges. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

Life Science 59

Life Science Drugs Development Research 59

XTalks

JUNE 16, 2023

Foundation Medicine recently announced that the US Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to serve as a companion diagnostic for identifying metastatic colorectal cancer patients with BRAF V600E alterations, suitable for treatment with Pfizer’s Braftovi (encorafenib) with cetuximab.

FDA Approval 97

FDA Approval Genome Genomics DNA 97

XTalks

JANUARY 9, 2023

The US Food and Drug Administration (FDA) granted Roche’s Lunsumio (mosunetuzumab) an accelerated approval near the end of 2022 for the treatment of adult patients with relapsed or refractory follicular lymphoma. It was approved in the EU for the same indication in June last year.

FDA Approval 98

FDA Approval Gene Therapy Antibody Gene 98

XTalks

FEBRUARY 5, 2024

GSK declared Arexvy to be a blockbuster in its first year on the market after higher-than-expected sales. GSK said it has secured about two-thirds share of the US market where nearly all of Arexvy’s sales were recorded. In addition to promoting uptake in the US, GSK and Pfizer are also focused on expanding in the global market.

Vaccination 59

Vaccination Vaccine Marketing Sales 59

XTalks

APRIL 17, 2023

Monoclonal antibodies are gaining attention as alternative or additive treatments for atopic dermatitis. Lebrikizumab is a new and investigational monoclonal antibody designed to selectively inhibit IL-13. “In According to Market Data Forecast, the global atopic dermatitis market size was valued at $13.5

Dermatology 97

Dermatology Antibody Clinical Trials Clinical Trials 97

pharmaphorum

SEPTEMBER 30, 2022

However, despite the growing number of available products focusing on the same target, prices are not showing the significant decrease that one might expect from a rapidly commoditising market. sugemalimab) to market at “radically lower”, disruptive price points when compared to current options1.

Life Science 91

Life Science Marketing Drugs Production 91

XTalks

NOVEMBER 22, 2022

Provention Bio’s Tzield (teplizumab) has won US Food and Drug Administration (FDA) approval to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older who have stage 2 type 1 diabetes. Related: GLP-1 Agonists for Diabetes: Mounjaro Versus Ozempic.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

XTalks

JUNE 30, 2023

It’s been a big week for cell and gene therapy approvals in the US, including a much-awaited approval for one to treat hemophilia A, the most common form of hemophilia. The approval came after a couple of setbacks, including a rejection in 2020 and a delay earlier this year.

Gene Therapy 98

Gene Therapy Gene FDA Approval Antibody 98

XTalks

AUGUST 15, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday that the US Food and Drug Administration (FDA) has granted marketing authorization for its combination treatment Akeega for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.

FDA Approval 52

FDA Approval Gene Hormones Licensing 52

XTalks

MAY 30, 2024

The FDA’s decision under the Prescription Drug User Fee Act (PDUFA) is anticipated by June 21, 2024. Vyvgart Hytrulo is a subcutaneous formulation that combines efgartigimod alfa, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20. In early 2021, the FDA approved Pfizer’s Panzyga for the treatment of CIDP.

FDA Approval 40

FDA Approval Immune Response Trials Drug Delivery 40

XTalks

MARCH 6, 2024

Despite the disappointing launch of Aduhelm and questions around Leqembi, companies like Eli Lilly are continuing to pursue their beta-amyloid monoclonal antibody therapies. Lilly is currently conducting a Phase III trial evaluating its beta-amyloid targeting monoclonal antibody, donanemab. billion in 2023, is anticipated to reach $96.4

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

MAY 29, 2024

The global pharmaceutical market has been expanding at an unprecedented pace. According to Statista , in 2023, the market was estimated to be worth about $1.6 The top ten pharma companies in 2023 by revenue accounted for about 35 percent of the market value, with total earnings of $559.5 billion, an increase of 10.8

Pharma Companies 52

Pharma Companies Sales FDA Approval Vaccination 52

Roots Analysis

DECEMBER 18, 2023

This novel modality emerged when pharmaceutical developers used non-antibody-based entities as targeting ligand to develop targeted therapeutics. Similar to the structure of the antibody drug conjugates, these next generation drug conjugates use a non-antibody-based targeting ligand, a cytotoxic payload and a linker.

Drugs 40

Drugs FDA Approval Antibody Development 40

XTalks

JUNE 20, 2023

Columvi is a bispecific antibody designed to bind to CD3 on the surface of T cells and CD20 on the surface of B cells in a novel 1:2 structural format where one region of the antibody binds to CD3 and two to CD20.

Antibody 98

Antibody Trials Drugs FDA Approval 98

XTalks

MAY 1, 2023

Market Potential of Qalsody In the US, there are currently an estimated 16,000 to 32,000 individuals living with ALS, while worldwide there are approximately 168,000 ALS patients, with only about 2 percent of them impacted by SOD1 mutations. Developed by Eisai and Biogen, Leqembi is an amyloid beta-directed antibody.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

XTalks

MAY 29, 2024

The Financial Times’ list of the Americas’ Fastest Growing Companies 2024 provides an insight into the market’s leaders in terms of growth, highlighting not the size of companies but their capacity for innovation. The list features companies from all spheres such as IT, Marketing, Finance and more.

Medicine 52

Medicine Marketing FDA Approval Development 52

XTalks

FEBRUARY 26, 2024

Xolair is the first medication approved by the FDA to reduce allergic reactions to more than one type of food after accidental exposure. Xolair is a monoclonal antibody that binds to IgE, a type of antibody in the body that triggers allergic reactions, to block it from binding to its receptors.

Allergies 100

Allergies FDA Approval Drugs Protein 100

Delveinsight

JANUARY 19, 2021

This is not something new in the Alzheimer’s disease market. A Sweet Year For Daiichi/ AZ As Enhertu Gets FDA Approval For Gastric Cancer. Enhertu is an antibody-drug conjugate (ADC) that comprises a humanized anti-HER2 IgG1 monoclonal antibody.

Manufacturing 40

Manufacturing Gene Therapy Life Science FDA Approval 40

Drug Discovery World

DECEMBER 13, 2023

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

XTalks

MARCH 8, 2024

The biosimilar injections, Jubbonti (denosumab-bddz) and Wyost (denosumab-bddz), are approved as interchangeable biosimilars to Prolia and Xgeva, respectively. Despite the approvals, the market launches of Jubbonti and Wyost are uncertain due to ongoing patent litigation between Sandoz and Amgen.

Drugs 59

Drugs FDA Approval Production Immune Response 59

Pharmaceutical Technology

DECEMBER 22, 2022

AstraZeneca and Daiichi Sankyo win the Business Expansion award this year as their collaboration bears more fruit in terms of new approvals. Financing recognises companies and institutions that have raised significant capital during the research period whether it be through corporate finance, the capital markets or fund raising.

Insulin 130

Insulin Production Development Genetics 130

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. The FDA has gone on to grant a fast review of the results ahead of a regulatory decision on the new lung cancer indication next year.

Marketing 78

Marketing Gene Silencing Gene Drugs 78

pharmaphorum

SEPTEMBER 21, 2021

” Ireland is the third-largest exporter of pharmaceuticals globally, according to IDA Ireland, with 50 FDA-approved manufacturing facilities generating annual exports of around €80 billion. “This significant investment will ensure the AstraZeneca supply network is fit for the future.”

Manufacturing 59

Manufacturing Life Science FDA Approval Medicine 59

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

DECEMBER 8, 2020

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies. . European venture capital firm Forbion rounded up $545 million for its fifth life sciences fund. Cornering the untapped Chinese CNS market, SciNeuro launched with $100 million in their pocket. Reduce cost.

RNA 52

RNA Antibody Life Science Protein 52

XTalks

MAY 25, 2021

AbbVie (NYSE:ABBV) continues to face heat over complaints of patent exploitation and price hikes of its world’s best-selling drug Humira (adalimumab) to build a market monopoly and block out Humira biosimilar competition. According to the FDA, biosimilars are among the most rapidly growing class of therapeutic products in the US.

Production 98

Production Drugs Marketing Sales 98

XTalks

OCTOBER 25, 2022

Imjudo is an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody that blocks the action of CTLA-4. Related: AstraZeneca’s Enhertu Gets FDA Approved as First Therapy for HER2-Low Breast Cancer. Imjudo is administered as a single dose with Imfinzi, followed by Imfinzi infusions every four weeks.

FDA Approval 98

FDA Approval Trials Immune Response Drugs 98

XTalks

JUNE 25, 2024

Approvals have shifted from vaccines, mRNA-based technologies and autologous cell therapies (ACTs) to cardio-metabolic products like GLP-1 receptor agonists, radiopharmaceuticals and antibody-drug conjugates (ADCs). In 2023, the total potential value of these alliances reached $125.3 percent from 2022.

Pharma Companies 52

Pharma Companies Production FDA Approval Vaccination 52

XTalks

NOVEMBER 16, 2022

has won US Food and Drug Administration (FDA) approval for its antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. The drug was approved under the FDA’s accelerated pathway and is indicated for adult patients with folate receptor alpha (FR?)-positive

FDA Approval 98

FDA Approval Antibody Drugs Protein 98

XTalks

DECEMBER 19, 2023

In the fast-evolving pharmaceutical landscape, tracking the top-selling drugs offers valuable insights into trends, healthcare priorities and the dynamics of the global market. With no competition in the market and impressive performance, Humira reported approximately $21.2 1) Comirnaty (COVID-19 Vaccine, mRNA) Sales in 2022: $37.81

Sales 64

Sales FDA Approval Drugs Vaccination 64

XTalks

NOVEMBER 7, 2022

Immunofluorescent staining of CTCs is a CTC isolation method that has been used since the first US Food and Drug Administration (FDA) approval in 2013 for the CellSearch ® CTC enumeration platform. Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

XTalks

MAY 31, 2023

Between 2021 and 2022, the biotech IPO market experienced a notable decline as investors grew increasingly cautious due to the uncertainties surrounding the pandemic and economic downturn. Another noteworthy candidate from Acelyrin’s pipeline is lonigutamab, an anti-IGF-1R monoclonal antibody administered via subcutaneous delivery.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97